左西孟旦用于左心室功能不全的心脏手术患者
这项多中心、随机、安慰剂对照的3期试验纳入左心室射血分数≤35%且使用体外循环行心脏手术的患者,随机接受静脉左西孟旦(0.2 μg/kg/min输注1小时,随后0.1 μg/kg/min输注23小时,术前开始)或安慰剂。849例改良意向治疗人群中,四组分主要终点(30天内死亡、30天内肾脏替代治疗、5天内围术期心肌梗死或5天内使用机械心脏辅助装置)在左西孟旦组428例中发生105例(24.5%),安慰剂组421例中发生103例(24.5%)(校正比值比1.00;99%CI 0.66–1.54;P=0.98)。两组主要终点及不良事件发生率均无显著差异。
要点
- 左西孟旦组四组分主要终点24.5%(105/428)vs 安慰剂组24.5%(103/421),校正比值比1.00(99%CI 0.66–1.54;P=0.98)。
- 两组主要终点(30天内死亡或5天内使用机械心脏辅助装置)左西孟旦组13.1%(56例)vs 安慰剂组11.4%(48例),校正比值比1.18(96%CI 0.76–1.82;P=0.45)。
- 两组不良事件发生率无显著差异。
- 预防性左西孟旦未降低左心室射血分数≤35%心脏手术患者的短期复合终点发生率。
适用人群与场景
- 左心室射血分数≤35%且使用体外循环行心脏手术的患者。
处置流程与药物剂量
- 左西孟旦组:静脉输注0.2 μg/kg/min持续1小时,随后0.1 μg/kg/min持续23小时,输注在术前开始。
研究设计与关键结果
- 多中心、随机、安慰剂对照、3期试验,882例随机化,849例改良意向治疗人群。
- 四组分主要终点(30天内死亡、30天内肾脏替代治疗、5天内围术期心肌梗死或5天内使用机械心脏辅助装置):左西孟旦组24.5%(105/428)vs 安慰剂组24.5%(103/421),校正比值比1.00(99%CI 0.66–1.54;P=0.98)。
- 两组分主要终点(30天内死亡或5天内使用机械心脏辅助装置):左西孟旦组13.1%(56例)vs 安慰剂组11.4%(48例),校正比值比1.18(96%CI 0.76–1.82;P=0.45)。
- 两组不良事件发生率无显著差异。
证据类型、等级与局限
- 证据类型:多中心、随机、安慰剂对照、3期试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在左心室射血分数≤35%且使用体外循环行心脏手术的患者中,预防性使用左西孟旦未能降低30天内死亡、肾脏替代治疗、围术期心肌梗死或使用机械心脏辅助装置的复合终点发生率。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Levosimendan is an inotropic agent that has been shown in small studies to prevent or treat the low cardiac output syndrome after cardiac surgery.
METHODS: In a multicenter, randomized, placebo-controlled, phase 3 trial, we evaluated the efficacy and safety of levosimendan in patients with a left ventricular ejection fraction of 35% or less who were undergoing cardiac surgery with the use of cardiopulmonary bypass. Patients were randomly assigned to receive either intravenous levosimendan (at a dose of 0.2 μg per kilogram of body weight per minute for 1 hour, followed by a dose of 0.1 μg per kilogram per minute for 23 hours) or placebo, with the infusion started before surgery. The two primary end points were a four-component composite of death through day 30, renal-replacement therapy through day 30, perioperative myocardial infarction through day 5, or use of a mechanical cardiac assist device through day 5; and a two-component composite of death through day 30 or use of a mechanical cardiac assist device through day 5.
RESULTS: A total of 882 patients underwent randomization, 849 of whom received levosimendan or placebo and were included in the modified intention-to-treat population. The four-component primary end point occurred in 105 of 428 patients (24.5%) assigned to receive levosimendan and in 103 of 421 (24.5%) assigned to receive placebo (adjusted odds ratio, 1.00; 99% confidence interval [CI], 0.66 to 1.54; P=0.98). The two-component primary end point occurred in 56 patients (13.1%) assigned to receive levosimendan and in 48 (11.4%) assigned to receive placebo (adjusted odds ratio, 1.18; 96% CI, 0.76 to 1.82; P=0.45). The rate of adverse events did not differ significantly between the two groups.
CONCLUSIONS: Prophylactic levosimendan did not result in a rate of the short-term composite end point of death, renal-replacement therapy, perioperative myocardial infarction, or use of a mechanical cardiac assist device that was lower than the rate with placebo among patients with a reduced left ventricular ejection fraction who were undergoing cardiac surgery with the use of cardiopulmonary bypass. (Funded by Tenax Therapeutics; LEVO-CTS ClinicalTrials.gov number, NCT02025621 .).
参考来源
- Mehta RH, Leimberger JD, van Diepen S, et al. Levosimendan in Patients with Left Ventricular Dysfunction Undergoing Cardiac Surgery. N Engl J Med. 2017. PMID: 28316276. doi:10.1056/NEJMoa1616218
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。